Progression-Free Survival: Meaningful or Simply Measurable?BOOTH, Christopher M; EISENHAUER, Elizabeth A.Journal of clinical oncology. 2012, Vol 30, Num 10, pp 1030-1033, issn 0732-183X, 4 p.Article

Proposal for the use of progression-free survival in unblinded randomized trialsFREIDLIN, Boris; KORN, Edward L; HUNSBERGER, Sally et al.Journal of clinical oncology. 2007, Vol 25, Num 15, pp 2122-2126, issn 0732-183X, 5 p.Article

The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free SurvivalSULLIVAN, Daniel Carl; SCHWARTZ, Lawrence H; BINSHENG ZHAO et al.Clinical cancer research (Print). 2013, Vol 19, Num 10, pp 2621-2628, issn 1078-0432, 8 p.Article

Comparison of Power Between Randomized Discontinuation Design and Upfront Randomization Design on Progression-Free SurvivalPINGFU FU; DOWLATI, Afshin; SCHLUCHTER, Mark et al.Journal of clinical oncology. 2009, Vol 27, Num 25, pp 4135-4141, issn 0732-183X, 7 p.Article

Issues in Using Progression-Free Survival When Evaluating Oncology ProductsFLEMING, Thomas R; ROTHMANN, Mark D; LU, Hong Laura et al.Journal of clinical oncology. 2009, Vol 27, Num 17, pp 2874-2880, issn 0732-183X, 7 p.Article

Les inhibiteurs des tyrosine kinases dans les cancers thyroïdiens : Cancers de la thyroïde: aspects innovants = Tyrosine kinase inhibitors in thyroid cancerILLOUZ, F.La Lettre du cancérologue (Boulogne). 2011, Vol 20, Num 5, pp 328-331, issn 1165-113X, 4 p.Article

Critères et méthodologie d'évaluation au remboursement des anticancéreux = Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical NeedDE SAHB-BERKOVITCH, Rima; WORONOFF-LEMSI, Marie-Christine; MOLIMARD, Mathieu et al.Thérapie (Paris). 2010, Vol 65, Num 4, pp 367-377, issn 0040-5957, 11 p.Article

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials : Important Design Element or Unnecessary Expense?DODD, Lori E; KORN, Edward L; FREIDLIN, Boris et al.Journal of clinical oncology. 2008, Vol 26, Num 22, pp 3791-3796, issn 0732-183X, 6 p.Article

Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical TrialsSRIDHARA, Rajeshwari; MANDREKAR, Sumithra J; DODD, Lori E et al.Clinical cancer research (Print). 2013, Vol 19, Num 10, pp 2613-2620, issn 1078-0432, 8 p.Article

Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid TumorsKORN, Ronald L; CROWLEY, John J.Clinical cancer research (Print). 2013, Vol 19, Num 10, pp 2607-2612, issn 1078-0432, 6 p.Article

Nouveau standard de chimiothérapie dans le traitement des tumeurs germinales non séminomateuses de mauvais pronostic: résultats de l'étude GETUG 13 = New standard of chemotherapy in the treatment of poor prognosis nonseminomatous germ cell tumors: results of GETUG 13 trialFLECHON, A; BOYLE, H.Correspondances en onco-urologie. 2013, Vol 4, Num 4, pp 142-147, issn 2110-087X, 6 p.Article

Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor PresentationSALAS, Sébastien; DUFRESNE, Armelle; OBERLIN, Odile et al.Journal of clinical oncology. 2011, Vol 29, Num 26, pp 3553-3558, issn 0732-183X, 6 p.Article

Actualités 2010 dans la chirurgie des cancers de l'ovaireCLASSE, Jean-Marc.Oncologie (Paris). 2011, Vol 13, Num 3, issn 1292-3818, S7-S10, SUP1Article

Detecting an Overall Survival Benefit that Is Derived From Progression-Free SurvivalBROGLIO, Kristine R; BERRY, Donald A.Journal of the National Cancer Institute. 2009, Vol 101, Num 23, pp 1642-1649, issn 0027-8874, 8 p.Article

La trabectédine dans les sarcomes des tissus mous : ECCO 14 - Barcelone - 24 septembre 2007LE CESNE, Axel; DOMONT, Julien.Oncologie (Paris). 2008, Vol 10, issn 1292-3818, 11 p., SUP1Serial Issue

Tumor Burden Modeling Versus Progression-Free Survival for Phase II Decision MakingKAISER, Lee D.Clinical cancer research (Print). 2013, Vol 19, Num 2, pp 314-319, issn 1078-0432, 6 p.Article

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II TrialsKORN, Edward L; LIU, Ping-Yu; PARULEKAR, Wendy et al.Journal of clinical oncology. 2008, Vol 26, Num 4, pp 527-534, issn 0732-183X, 8 p.Article

Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA EraDESIREDDI, Naresh V; ROEHL, Kimberly A; LOEB, Stacy et al.Urology (Ridgewood, NJ). 2007, Vol 70, Num 5, pp 950-955, issn 0090-4295, 6 p.Article

Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysisAMIT, O; MANNINO, F; STONE, A. M et al.European journal of cancer (1990). 2011, Vol 47, Num 12, pp 1772-1778, issn 0959-8049, 7 p.Article

Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndromeZHUANG ZUO; CALIN, George A; DE PAULA, Henrique M et al.Blood. 2011, Vol 118, Num 2, pp 413-415, issn 0006-4971, 3 p.Article

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsGAY, Francesca; LAROCCA, Alessandra; PETRUCCI, Maria T et al.Blood. 2011, Vol 117, Num 11, pp 3025-3031, issn 0006-4971, 7 p.Article

Residual Serum Monoclonal Protein Predicts Progression-Free Survival in Patients With Previously Untreated Multiple MyelomaSCHAEFER, Eric W; KUMAR, Shaji; DISPENZIERI, Angela et al.Cancer. 2010, Vol 116, Num 3, pp 640-646, issn 0008-543X, 7 p.Article

Clinical benefit of early phase clinical trial participation for advanced sarcoma patientsJONES, Robin L; OLMOS, David; THWAY, Khin et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 2, pp 423-429, issn 0344-5704, 7 p.Article

Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trialsTANG, P. A; POND, G. R; CHEN, E. X et al.Annals of oncology. 2010, Vol 21, Num 1, pp 19-26, issn 0923-7534, 8 p.Article

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerBURZYKOWSKI, Tomasz; BUYSE, Marc; JASSEM, Jacek et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1987-1992, issn 0732-183X, 6 p.Article